Article Text

PDF
Systematic review
Stroke rates vary substantially across cohorts of patients with atrial fibrillation
  1. Luciano A Sposato1,2,
  2. Gustavo Saposnik3,4
  1. 1Department of Clinical Neurological Sciences and Department of Anatomy and Cell Biology, Western University, London, Ontario, Canada
  2. 2Stroke, Dementia and Heart Disease Laboratory, Western University, London, Ontario, Canada
  3. 3Faculty of Medicine, Division of Neurology, Department of Medicine, Stroke Outcomes Research Center, St. Michael's Hospital and Institute of Health Policy, Management and Evaluation, University of Toronto, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
  4. 4Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
  1. Correspondence to : Dr Gustavo Saposnik, Division of Neurology, Department of Medicine, St Michael's Hospital, University of Toronto, 55 Queen Street East, Toronto, ON M5C 1R6, Canada; saposnikg{at}smh.ca

Statistics from Altmetric.com

Commentary on: OpenUrlAbstract/FREE Full Text

Context

Oral anticoagulants (OACs) substantially reduce stroke risk in patients with atrial fibrillation (AF); however, they remain globally underused.1 One of the main reasons is the difficulty in stratifying AF-related ischaemic stroke risk at the individual patient level.1 ,2 Among scores stratifying AF-related stroke risk, CHA2-DS2-Vasc prevails in most recent international AF guidelines.3 ,4 Still, it remains unknown whether AF-related stroke risk is stable across regions, international cohorts or within specific CHA2-DS2-Vasc score strata.

Methods

This systematic review included only studies reporting ischaemic stroke rates for patients with AF not on OACs, and assessed …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.